Maria Caterina Rotiroti

This study develops a dual CAR-T therapy targeting CD33 and TIM-3 in AML, showing improved specificity and efficacy through glycosylation-modulated TIM-3 recognition.

The paper introduces Sphyder, a tool to detect and rewire phosphorylation motifs, revealing PD-1 signaling mechanisms and enabling synthetic receptor design for immunotherapy.

This study shows that CAR T cell therapy in mice causes cognitive impairment through CNS immune dysregulation, microglial reactivity, and disrupted oligodendroglial homeostasis.

This study identifies IKAROS as a factor associated with antigen escape in B-ALL, showing that low IKAROS levels lead to reduced B-cell antigen expression and resistance to CD19- and CD22-targeted therapies.

This paper introduces a novel CAR T cell platform using proximal T cell signaling molecules to enable Boolean logic-gated control, improving efficacy and reducing off-tumor toxicity.